Breaking News

Tweet TWEET

Multiplicom Appoints Dr. Ian Gilham as Chairman of the Board

         Multiplicom Appoints Dr. Ian Gilham as Chairman of the Board

  PR Newswire

  NIEL, Belgium, June 25, 2013

NIEL, Belgium, June 25, 2013 /PRNewswire/ --

Multiplicom NV, a specialist in the development, production and
commercialisation of innovative molecular genetic tests, today announces that
Dr Ian Gilham has been appointed as Chairman of the Board of Directors.

"We are delighted that Ian has decided to join our team, strengthening the
Board at this important time in the company's development," said Dirk Pollet
CEO of Multiplicom. "Ian has worked with many companies, providing them with
valuable experience in research, development and the commercialization of
products. We look forward to working with him and have every confidence that
his expertise will help us grow the company and deliver value for both new and
existing investors."

Dr. Gilham was Chief Executive Officer of Axis-Shield plc, a public in-vitro
diagnostics company, until Alere acquired it in November 2011. Whilst at
Axis-Shield, Dr. Gilham held the position of Chief Operating Officer and
became Chief Executive Officer in January 2008. Before joining Axis-Shield,
Dr. Gilham was VP Pharmacogenetics at GSK where he was responsible for the
delivery of pharmacogenetic tests, as well as novel diagnostic tests used in
targeting GSK's medicines. Prior to joining GSK, Dr. Gilham held international
general management, marketing, business development and R&D positions with
Abbott Laboratories, Celltech and Amersham, gaining wide expertise in the
fields of clinical diagnostics and pharmaceuticals.

Commenting on his appointment, Dr Ian Gilham said: "It is with great pleasure
that I have accepted the opportunity to become Chairman to the Board of
Multiplicom. The molecular diagnostics market is undergoing rapid growth,
fuelled by the decreasing cost of DNA sequencing and increased availability of
genetic information that links genes to health and disease. The outlook is
very promising for the genomic and somatic mutations that Multiplicom is
focused on. I look forward to working with the Board to make sure the company
fulfills its clearly evident potential."

About Multiplicom

Multiplicom ( http://www.multiplicom.com ) is a Belgian biotech company
focused on human molecular diagnostics. The company originated from the
research team of Dr. Jurgen Del-Favero at the VIB Department of Molecular
Genetics, University of Antwerp (UA), headed by Dr. Christine van Broeckhoven.
In April 2011 Gimv, Gimv-managed Biotechfonds Vlaanderen, VIB and UA invested
a total of 2 million Euro in the series A financing. In February 2013,
Multiplicom closed its series B financing raising 5.5 million Euro from a
consortium composed of the series A and new investors (PMV, RMM and Qbic ARKIV
Fund) to expedite development of additional diagnostic tests, fund
international validation studies and expand sales channels.

For more information, please contact: Dr Dirk Pollet, CEO Multiplicom T
+32-478-376-369 - e-mail: dirk.pollet@multiplicom.com Mary-Jane Elliott,
M:Communications T +44(0)20-7920-2345 - e-mail: elliott@mcomgroup.com
 
Press spacebar to pause and continue. Press esc to stop.